Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia

American Journal of Health-System Pharmacy

Volumn 59, Issue 10, 2002, Pages 941-948

  Lang, Kathleen ^a   Menzin, Joseph ^a   Earle, Craig C ^a   Mallick, Rajiv ^a  

^a Boston Health Economics Inc   (United States)

Author keywords

Antineoplastic agents; Combined therapy; Cytarabine; Drug comparisons; Gemtuzumab ozogamicin; Hospitals; Leukemia; Mitoxantrone; Mortality; Outcomes

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; TREATMENT OUTCOME;

EID: 0037092544     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.10.941     Document Type: Article

References (58)

1. Acute myeloid leukemia
2. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia
3. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years
4. Acute myelogenous leukemia: Recent advances in therapy
5. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update
6. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
7. Improved prospects for long-term survival in adults with acute myelogenous leukemia
8. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
9. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period
10. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
11. An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: Results of 8722, a randomized Phase II study conducted by Cancer and Leukemia Group B
12. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study
13. A Phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia
14. Prognostic factors at relapse for adults with acute myeloid leukemia
15. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML- 11, a Phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group
16. Granulocyte-macrophage colonystimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
17. Consensus report: 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
18. Planned progressive antimicrobial therapy in neutropenic patients
19. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia
20. Calicheamicin gamma II and DNA: Molecular recognition process responsible for site-specificity
21. The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score
22. Expression of normal myeloidassociated antigens by acute leukemia cells
23. Antibody-targeted chemotherapy of acute myeloid leukemia using an antiCD33 calicheamicin immunoconjugate, gemtuzumab ozogamicin
24. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients < 60 and ≥ 60 years of age with AML in first relapse
25. Epidemiology of acute leukemia in children and adults
26. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission
27. Potential reduction in risk of chemotherapy hospitalization associated with Mylotarg(TM) (gemtuzumab ozogamicin, CMA-676), an antibody-targeted chemotherapy, in treatment of older patients with relapsed acute myeloid leukemia
28. Economic evaluation of G-CSF use in the therapy of adult acute myelogenous leukemia (AML)
29. Cost impact of filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia (AML)
30. Economic analysis of GM-CSF as adjunct therapy for adults with AML
31. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
32. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission
33. The role of thiotepa in autologous bone marrow transplantation for acute leukemia
34. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
35. Fludarabine and granulocyte colonystimulating factor (G-CSF) in patients with chronic lymphocytic leukemia
36. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts
37. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia
38. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: A Phase I/II trial
39. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer
40. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: Results of 5-year follow-up
41. Adjuvant regional chemotherapy in advanced pancreatic cancer: Results of a prospective study
42. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma
43. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease
44. Lobectomy by video-assisted thoracic surgery for primary lung cancer: Experiences based on provisional indications
45. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes
46. Hodgkin's disease and transplantation: A room with a (nontransplanter's) view
47. Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy
48. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours
49. Interferonalpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: A pilot study
50. Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study
51. Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: Results of a prospective treatment protocol
52. A randomized placebo-controlled Phase III study of granulocyte-macrophage colonystimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
53. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031)
54. Economic analysis of a randomized placebo-controlled Phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia